Fujian Mindong opens Phase 3 test of dual H1/PAF blocker rupatifen in China
The registration adds a fifth direct competitor to a seasonal allergic rhinitis field where 26 prior Phase 3 trials on the same target completed without a single termination.
Executive Summary
- Fujian Mindong Rejuvenation Pharmaceutical has registered a Phase 3 trial testing rupatifen fumarate, a dual histamine H1 and platelet-activating factor receptor antagonist, against placebo and an active comparator in seasonal allergic rhinitis.
- The trial enters a mechanism-indication pairing that has produced dozens of completed Phase 3 studies with essentially no terminations, making replication of an established efficacy band the bar rather than proof of a new mechanism.
- The design's most telling choice is its head-to-head arm against rupatadine fumarate, a chemically related single-target antihistamine, positioning the added PAF-receptor activity as the feature under test.
- The trial has not yet begun recruiting, and its primary completion date sets the earliest point at which a nasal-symptom-score comparison against the active comparator and placebo will be available.
The registration
The trial, filed under NCT07711262, is a Phase 3, randomized, quadruple-masked study of rupatifen fumarate capsules in adults aged 18 to 65 with a documented history of seasonal allergic rhinitis of at least two years. It targets 550 participants and has not yet started recruiting, with a start date of July 1, 2026 and a primary completion date of October 1, 2027. The study runs across sites in China and carries three arms, consistent with a design built to compare the investigational drug, an active comparator, and placebo. NCT07711262Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisNCT07711262
The design
The registered primary endpoint is the change from baseline in the average reflective Total Nasal Symptom Score during the treatment period, a four-symptom composite (sneezing, rhinorrhea, nasal pruritus, and nasal congestion) scored 0 to 12, measured from Day 1 pre-dose through Day 15. Secondary endpoints span morning and evening symptom scores, ocular symptom scores, quality-of-life measures, and a battery of ECG safety parameters including QTcF, consistent with a cardiac-safety watch typical of antihistamine development. Eligible patients must show a reflective score of at least 6 points at screening, with a nasal congestion subscore of at least 2, before entering a one-week run-in period. NCT07711262Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisNCT07711262
The comparator choice
The trial names rupatadine fumarate as its active comparator alongside placebo, pairing the dual-mechanism candidate against a single-target antihistamine chemically related to it. That head-to-head design is the differentiation question the trial is built to answer: whether the added platelet-activating factor receptor activity produces a nasal-symptom benefit beyond what histamine H1 blockade alone delivers, a hypothesis the trial's own comparator arm will test directly. NCT07711262Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisNCT07711262
The competitive field
Direct competitors sharing the same target and mechanism class include Shandong New Time Pharmaceutical's cetirizine hydrochloride, Sanofi's fexofenadine, Sandoz's mometasone/azelastine combination, Abdi Ibrahim's AI201901, and Viatris's azelastine, all in Phase 3 or Phase 2 testing for allergic rhinitis or related indications. Across 74 trials pairing the histamine H1 receptor with seasonal allergic rhinitis since 1995, 26 Phase 3 studies have completed with no terminations recorded, and only three sponsors across the broader dataset have registered a failure in this pairing. Field activity for the target has declined over time, with recent trial volume running at roughly 2% of its historical peak, even as the indication itself continues drawing new entrants, including monoclonal antibodies targeting IL-4Rα such as Genrix's GR1802 and Chengdu Kangnuoxing's stapokibart, both also in Phase 3 for the same indication. Against that backdrop, a validated small-molecule mechanism class, this trial's information value lies less in proving the biology works and more in whether the dual-receptor combination shows separation from single-target agents like rupatadine on the same nasal-symptom composite.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.